Physician profile
Daniel John Sung
NPI 1588619969
$4,808.67
in general payments reported to CMS, 2019-2025
29 companies · $1,400 in 2025
The $1,400 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.99 · 2020: $144 · 2021: $268 · 2022: $517 · 2023: $1,245 · 2024: $1,208 · 2025: $1,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,853.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $668.56 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $535.77 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $501.83 | 2021-2025 | Vraylar |
| Lilly USA, LLC | $475.43 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $445.37 | 2020-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Exact Sciences Corporation | $380.95 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $223.00 | 2023-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $215.22 | 2021-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $200.56 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $177.63 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $164.81 | 2022-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $157.09 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $142.78 | 2020-2022 | |
| Pfizer INC. | $133.78 | 2021-2025 | |
| Dexcom, INC. | $55.69 | 2021-2025 | Dexcom G6 Transmitter |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $48.55 | 2021-2022 | |
| Amarin Pharma, INC. | $30.50 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $30.27 | 2022 | |
| Urogen Pharma, INC. | $26.67 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.99 | 2019 | |
| Abbott Laboratories | $22.88 | 2024 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $22.13 | 2023 | Rexulti |
| Hologic Sales and Service, LLC | $21.36 | 2024 | Aptima |
| E.R. Squibb & Sons, L.L.C. | $19.97 | 2024 | Camzyos |
| Verona Pharma, INC. | $19.90 | 2025 | Ohtuvayre |
| Teva Pharmaceuticals USA, INC. | $17.08 | 2023 | Austedo Xr |
| Shield Therapeutics INC | $15.27 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $15.19 | 2025 | Zoryve |
| Phathom Pharmaceuticals, INC. | $14.44 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.